Characterization of 2 Novel Phosphodiesterase 2 Inhibitors Hcyb1 and PF-05180999 on Depression- and Anxiety-Like Behavior

Abstract

Phosphodiesterase 2A (PDE2A) represents a novel target for new therapies addressing psychiatric disorders. To date, the development of PDE2A inhibitors suitable for human clinical evaluation has been hampered by the poor brain accessibility and metabolic stability of the available compounds.

Document Details

Document Type
Pub Defense Publication
Publication Date
May 19, 2023
Source ID
10.1093/ijnp/pyad020

Entities

People

  • Abhinav P. Acharya
  • Chang-Guo Zhan
  • Fu Du
  • Jianghong Ye
  • Wei Wang
  • Xiongwei Zhu
  • Ying Xu
  • Yue M. Lu
  • Yuhan Zhao
  • Yuqing Yan

Organizations

  • Arizona State University
  • Case Western Reserve University
  • National Institute on Aging
  • Rutgers University
  • University of Arizona
  • University of Kentucky

Tags

Fields of Study

  • Medicine
  • Psychology

Readers

  • Mental Health of Military Veterans with Posttraumatic Stress Disorder (PTSD): Risk Factors, Prevalence, Symptoms, and Treatment.
  • Molecular and Cellular Biochemistry
  • Systems Analysis and Design